Synthetic and bioinspired cage nanoparticles for drug delivery

Nanomedicine

Volumn 9, Issue 10, 2014, Pages 1545-1564

  Deshayes, Stephanie ^a   Gref, Ruxandra ^b  

^a Engineering IV   (United States)

^b INSTITUT DES SCIENCES MOLÉCULAIRES D ORSAY   (France)

Author keywords

cage nanoparticles; calixarene; cucurbituril; cyclodextrin; drug delivery; host guest interactions; metal organic framework; protein cages

Indexed keywords

ADAMANTANE; CAGE NAOPARTICLE; CALIXARENE; CISPLATIN; CYCLODEXTRIN; DOXORUBICIN; FERRITIN; FUROSEMIDE; INSULIN; LEUCINE ENKEPHALIN[2 DEXTRO ALANINE 6 ARGININE]; METAL ORGANIC FRAMEWORK; NANOCARRIER; NANOPARTICLE; PACLITAXEL; SMALL HEAT SHOCK PROTEIN; TRICLOSAN; UNCLASSIFIED DRUG; BIOMIMETIC MATERIAL; DRUG; NANOCAPSULE;

BIOMEDICINE; DRUG DELIVERY SYSTEM; DRUG RELEASE; HUMAN; NANOENCAPSULATION; NONHUMAN; REVIEW; VIRUS LIKE AGENT; CHEMISTRY; DRUG DESIGN; PARTICLE SIZE; SYNTHESIS; ULTRASTRUCTURE;

BIOMIMETIC MATERIALS; DRUG DESIGN; NANOCAPSULES; PARTICLE SIZE; PHARMACEUTICAL PREPARATIONS;

EID: 84907468753     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.14.67     Document Type: Review

References (155)

1. Cram DJ. The design of molecular hosts, guests, and their complexes (Nobel Lecture). Angew. Chem. Int. Ed. Engl. 27(8), 1009-1020 (1988).
2. Pedersen CJ. The discovery of crown ethers (Noble Lecture). Angew. Chem. Int. Ed. Engl. 27(8), 1021-1027 (1988).
3. Lehn J-M. Supramolecular chemistry -scope and Pperspectives molecules, supermolecules, and molecular devices (Nobel Lecture). Angew. Chem. Int. Ed. Engl. 27(1), 89-112 (1988).
4. Böhmer V. Calixarenes, macrocycles with (almost) unlimited possibilities. Angew. Chem. Int. Ed. Engl. 34(7), 713-745 (1995).
5. Tashiro K, Aida T. Metalloporphyrin hosts for supramolecular chemistry of fullerenes. Chem. Soc. Rev. 36(2), 189-197 (2007).
6. Wenz G. Cyclodextrins as building blocks for supramolecular structures and functional units. Angew. Chem. Int. Ed. Engl. 33(8), 803-822 (1994).
7. Boas U, Heegaard PMH. Dendrimers in drug research. Chem. Soc. Rev. 33(1), 43-63 (2004).
8. Seel C, Vögtle F. Molecules with large cavities in supramolecular chemistry. Angew. Chem. Int. Ed. Engl. 31(5), 528-549 (1992).
9. Lagona J, Mukhopadhyay P, Chakrabarti S, Isaacs L. The Cucurbit[n]uril family. Angew. Chem. Int. Ed. Engl. 44(31), 4844-4870 (2005).
10. Maham A, Tang Z, Wu H, Wang J, Lin Y. Protein-based nanomedicine platforms for drug delivery. Small 5(15), 1706-1721 (2009).
11. Lee LA, Wang Q. Adaptations of nanoscale viruses and other protein cages for medical applications. Nanomedicine 2(3), 137-149 (2006).
12. Ma Y, Nolte RJM, Cornelissen JJLM. Virus-based nanocarriers for drug delivery. Adv. Drug Deliv. Rev. 64(9), 811-825 (2012).
13. Garcea RL, Gissmann L. Virus-like particles as vaccines and vessels for the delivery of small molecules. Curr. Opin. Biotechnol. 15(6), 513-517 (2004).
14. Kaiser CR, Flenniken ML, Gillitzer E, et al. Biodistribution studies of protein cage nanoparticles demonstrate broad tissue distribution and rapid clearance in vivo. Int. J. Nanomed. 2(4), 715-733 (2007).
15. Singh P, Prasuhn D, Yeh RM, et al. Bio-distribution, toxicity and pathology of cowpea mosaic virus nanoparticles in vivo. J. Control. Release 120(1-2), 41-50 (2007).
16. Oriordan CR, Lachapelle A, Delgado C, et al. PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum. Gene Ther. 10(8), 1349-1358 (1999).
17. Raja KS, Wang Q, Gonzalez MaJ, Manchester M, Johnson JE, Finn MG. Hybrid virus-polymer materials. 1. Synthesis and properties of PEG-decorated cowpea mosaic virus. Biomacromolecules 4(3), 472-476 (2003).
18. Kovacs EW, Hooker JM, Romanini DW, Holder PG, Berry KE, Francis MB. Dual-surface-modified bacteriophage MS2 as an ideal scaffold for a viral capsid-based drug delivery system. Bioconjugate Chem. 18(4), 1140-1147 (2007).
19. Wu Y, Yang H, Shin H-J. Viruses as self-assembled nanocontainers for encapsulation of functional cargoes. Korean J. Chem. Eng. 30(7), 1359-1367 (2013).
20. Bancroft JB, Hiebert E, Bracker CE. The effects of various polyanions on shell formation of some spherical viruses. Virology 39(4), 924-930 (1969).
21. Van Der Graaf M, Van Mierlo CPM, Hemminga MA. Solution conformation of a peptide fragment representing a proposed RNA-binding site of a viral coat protein studied by two-dimensional NMR. Biochemistry 30(23), 5722-5727 (1991).
22. Speir JA, Munshi S, Wang G, Baker TS, Johnson JE. Structures of the native and swollen forms of cowpea chlorotic mottle virus determined by x-ray crystallography and cryo-electron microscopy. Structure 3(1), 63-78 (1995).
23. Douglas T, Young M. Host-guest encapsulation of materials by assembled virus protein cages. Nature 393(6681), 152-155 (1998).
24. Douglas T, Strable E, Willits D, Aitouchen A, Libera M, Young M. Protein engineering of a viral cage for constrained nanomaterials synthesis. Adv. Mater. 14(6), 415-418 (2002).
25. Brasch M, De La Escosura A, Ma Y, et al. Encapsulation of phthalocyanine supramolecular stacks into virus-like particles. J. Am. Chem. Soc. 133(18), 6878-6881 (2011).
26. Daniel M-C, Tsvetkova IB, Quinkert ZT, et al. Role of surface charge density in nanoparticle-templated assembly of bromovirus protein cages. ACS Nano 4(7), 3853-3860 (2010).
27. Dixit SK, Goicochea NL, Daniel M-C, et al. Quantum dot encapsulation in viral capsids. Nano Lett. 6(9), 1993-1999 (2006).
28. Loo L, Guenther RH, Lommel SA, Franzen S. Encapsidation of nanoparticles by red clover necrotic mosaic virus. J. Am. Chem. Soc. 129(36), 11111-11117 (2007).
29. Li F, Zhang Z-P, Peng J, et al. Imaging viral behavior in mammalian cells with self-assembled capsid-quantum-dot hybrid particles. Small 5(6), 718-726 (2009).
30. Goicochea NL, De M, Rotello VM, Mukhopadhyay S, Dragnea B. Core-like particles of an enveloped animal virus can self-assemble efficiently on artificial templates. Nano Lett. 7(8), 2281-2290 (2007).
31. Fiedler JD, Brown SD, Lau JL, Finn MG. RNA-directed packaging of enzymes within virus-like particles. Angew. Chem. Int. Ed. 49(50), 9648-9651 (2010).
32. Oneil A, Reichhardt C, Johnson B, Prevelige PE, Douglas T. Genetically programmed in vivo packaging of protein cargo and its controlled release from bacteriophage P22. Angew. Chem. Int. Ed. 50(32), 7425-7428 (2011).
33. Patterson DP, Prevelige PE, Douglas T. Nanoreactors by programmed enzyme encapsulation inside the capsid of the bacteriophage P22. ACS Nano 6(6), 5000-5009 (2012).
34. Oneil A, Prevelige PE, Basu G, Douglas T. Coconfinement of fluorescent proteins: spatially enforced communication of GFP and mCherry encapsulated within the P22 capsid. Biomacromolecules 13(12), 3902-3907 (2012).
35. Patterson DP, Lafrance B, Douglas T. Rescuing recombinant proteins by sequestration into the P22 VLP. Chem. Commun. 49(88), 10412-10414 (2013).
36. Patterson DP, Schwarz B, Waters RS, Gedeon T, Douglas T. Encapsulation of an enzyme cascade within the bacteriophage P22 virus-like particle. ACS Chem. Biol. 9(2), 359-365 (2013).
37. Wörsdörfer B, Woycechowsky KJ, Hilvert D. Directed evolution of a protein container. Science 331(6017), 589-592 (2011).
38. Wörsdörfer B, Pianowski Z, Hilvert D. Efficient in vitro encapsulation of protein cargo by an engineered protein container. J. Am. Chem. Soc. 134(2), 909-911 (2011).
39. Yildiz I, Lee KL, Chen K, Shukla S, Steinmetz NF. Infusion of imaging and therapeutic molecules into the plant virus-based carrier cowpea mosaic virus: cargo-loading and delivery. J. Controlled Release 172(2), 568-578 (2013).
40. Aljabali AaA, Shukla S, Lomonossoff GP, Steinmetz NF, Evans DJ. CPMV-DOX delivers. Mol. Pharm. 10(1), 3-10 (2012).
41. Pokorski JK, Steinmetz NF. The art of engineering viral nanoparticles. Mol. Pharm. 8(1), 29-43 (2010).
42. Strable E, Prasuhn DE, Udit AK, et al. Unnatural amino acid incorporation into virus-like particles. Bioconjugate Chem. 19(4), 866-875 (2008).
43. Steinmetz NF, Hong V, Spoerke ED, et al. Buckyballs meet viral nanoparticles: candidates for biomedicine. J. Am. Chem. Soc. 131(47), 17093-17095 (2009).
44. Patel KG, Swartz JR. Surface functionalization of virus-like particles by direct conjugation using azide-alkyne click chemistry. Bioconjugate Chem. 22(3), 376-387 (2011).
45. Prasuhn JDE, Yeh RM, Obenaus A, Manchester M, Finn MG. Viral MRI. contrast agents: coordination of Gd by native virions and attachment of Gd complexes by azide-alkyne cycloaddition. Chem. Commun. 28(12), 1269-1271 (2007).
46. Astronomo RD, Kaltgrad E, Udit AK, et al. Defining criteria for oligomannose immunogens for HIV using icosahedral virus capsid scaffolds. Chem. Biol. 17(4), 357-370 (2010).
47. Banerjee D, Liu AP, Voss NR, Schmid SL, Finn MG. Multivalent display and receptor-mediated endocytosis of transferrin on virus-like particles. ChemBioChem 11(9), 1273-1279 (2010).
48. Rhee J-K, Baksh M, Nycholat C, Paulson JC, Kitagishi H, Finn MG. Glycan-targeted virus-like nanoparticles for photodynamic therapy. Biomacromolecules 13(8), 2333-2338 (2012).
49. Pokorski JK, Breitenkamp K, Liepold LO, Qazi S, Finn MG. Functional virus-based polymer-protein nanoparticles by atom transfer radical polymerization. J. Am. Chem. Soc. 133(24), 9242-9245 (2011).
50. Lucon J, Qazi S, Uchida M, et al. Use of the interior cavity of the P22 capsid for site-specific initiation of atom-transfer radical polymerization with high-density cargo loading. Nat. Chem. 4(10), 781-788 (2012).
51. Kang S, Uchida M, ONeil A, Li R, Prevelige PE, Douglas T. Implementation of P22 viral capsids as nanoplatforms. Biomacromolecules 11(10), 2804-2809 (2010).
52. Lockney DM, Guenther RN, Loo L, et al. The red clover necrotic mosaic virus capsid as a multifunctional cell targeting plant viral nanoparticle. Bioconjugate Chem. 22(1), 67-73 (2010).
53. Zeng Q, Wen H, Wen Q, et al. Cucumber mosaic virus as drug delivery vehicle for doxorubicin. Biomaterials 34(19), 4632-4642 (2013).
54. Ren Y, Wong SM, Lim L-Y. Folic acid-conjugated protein cages of a plant virus: A novel delivery platform for doxorubicin. Bioconjugate Chem. 18(3), 836-843 (2007).
55. Harrison PM, Hoy TG, Macara IG, Hoare RJ. Ferritin iron uptake and release. Structure-function relationships. Biochem. J. 143(2), 445-451 (1974).
56. Mann S, Bannister JV, Williams RJP. Structure and composition of ferritin cores isolated from human spleen, limpet (Patella vulgata) hemolymph and bacterial (Pseudomonas aeruginosa) cells. J. Mol. Biol. 188(2), 225-232 (1986).
57. Theil EC. Ferritin: structure, gene regulation, and cellular function in animals, plants, and microorganisms. Annu. Rev. Biochem. 56(1), 289-315 (1987).
58. Kasyutich O, Ilari A, Fiorillo A, Tatchev D, Hoell A, Ceci P. Silver ion incorporation and nanoparticle formation inside the cavity of pyrococcus furiosus ferritin: structural and size-distribution analyses. J. Am. Chem. Soc. 132(10), 3621-3627 (2010).
59. Li M, Viravaidya C, Mann S. Polymer-mediated synthesis of ferritin-encapsulated inorganic nanoparticles. Small 3(9), 1477-1481 (2007).
60. Ueno T, Suzuki M, Goto T, Matsumoto T, Nagayama K, Watanabe Y. Size-selective olefin hydrogenation by a Pd nanocluster provided in an apo-ferritin cage. Angew. Chem. Int. Ed. 43(19), 2527-2530 (2004).
61. Uchida M, Flenniken ML, Allen M, et al. Targeting of cancer cells with ferrimagnetic ferritin cage nanoparticles. J. Am. Chem. Soc. 128(51), 16626-16633 (2006).
62. Simsek E, Akif Kilic M. Magic ferritin: A novel chemotherapeutic encapsulation bullet. J. Magn. Magn. Mater. 293(1), 509-513 (2005).
63. Kilic MA, Ozlu E, Calis S. A novel protein-based anticancer drug encapsulating nanosphere: apoferritin-doxorubicin complex. J. Biomed. Nanotechnol. 8(3), 508-514 (2012).
64. Blazkova I, Nguyen H, Dostalova S, et al. Apoferritin modified magnetic particles as doxorubicin carriers for anticancer drug delivery. Int. J. Mol. Sci. 14(7), 13391-13402 (2013).
65. Zhen Z, Tang W, Chen H, et al. RGD-modified apoferritin nanoparticles for efficient drug delivery to tumors. ACS Nano 7(6), 4830-4837 (2013).
66. Zutphen SV, Reedijk J. Targeting platinum anti-tumour drugs: overview of strategies employed to reduce systemic toxicity. Coord. Chem. Rev. 249(24), 2845-2853 (2005).
67. Xing R, Wang X, Zhang C, et al. Characterization and cellular uptake of platinum anticancer drugs encapsulated in apoferritin. J. Inorg. Biochem. 103(7), 1039-1044 (2009).
68. Falvo E, Tremante E, Fraioli R, et al. Antibody-drug conjugates: targeting melanoma with cisplatin encapsulated in protein-cage nanoparticles based on human ferritin. Nanoscale 5(24), 12278-12285 (2013).
69. Santoro MG. Heat shock factors and the control of the stress response. Biochem. Pharmacol. 59(1), 55-63 (2000).
70. Sun Y, Macrae TH. Small heat shock proteins: molecular structure and chaperone function. Cell. Mol. Life Sci. 62(21), 2460-2476 (2005).
71. Kim KK, Kim R, Kim S-H. Crystal structure of a small heat-shock protein. Nature 394(6693), 595-599 (1998).
72. Bova MP, Huang Q, Ding L, Horwitz J. Subunit exchange, conformational stability, and chaperone-like function of the small heat shock Protein 16.5 from Methanococcus jannaschii. J. Biol. Chem. 277(41), 38468-38475 (2002).
73. Flenniken ML, Willits DA, Brumfield S, Young MJ, Douglas T. The small heat shock protein cage from Methanococcus jannaschii is a versatile nanoscale platform for genetic and chemical modification. Nano Lett. 3(11), 1573-1576 (2003).
74. Flenniken ML, Liepold LO, Crowley BE, Willits DA, Young MJ, Douglas T. Selective attachment and release of a chemotherapeutic agent from the interior of a protein cage architecture. Chem. Commun. (28(4), 447-449 (2005).
75. Toita R, Murata M, Abe K, et al. A nanocarrier based on a genetically engineered protein cage to deliver doxorubicin to human hepatocellular carcinoma cells. Chem. Commun. 49(67), 7442-7444 (2013).
76. Wang L, Li L-L, Fan Y-S, Wang H. Host-guest supramolecular nanosystems for cancer diagnostics and therapeutics. Adv. Mater. 25(28), 3888-3898 (2013).
77. Villiers A. Sur la transformation de la fécule en dextrine par le ferment butyrique. Compt. Rend. Fr. Acad. Sci., 435-438 (1891).
78. Loftsson T, Duchene D. Cyclodextrins and their pharmaceutical applications. Int. J. Pharm. 329(1-2), 1-11 (2007).
79. Gref R, Duchene D. Cyclodextrins as "smart" components of polymer nanoparticles. J. Drug Del. Sci. Tech. 22(3), (2012).
80. Da Silveira A, Ponchel G, Puisieux F, Duchene D. Combined poly(isobutylcyanoacrylate) and cyclodextrins nanoparticles for enhancing the encapsulation of lipophilic drugs. Pharm. Res. 15(7), 1051-1055 (1998).
81. Duchene D, Ponchel G, Boudad H, Monza Da Silveira A. Emploi des cyclodextrines dans la formulation de nanoparticules de poly(cyanoacrylate dalkyle) chargées en divers principes actifs. Ann. Pharm. Fr. 59(6), 384-391 (2001).
82. Monza Da Silveira A, Duchene D, Ponchel G. Drug release characteristics from combined poly(isobutylcyanoacrylate) and cyclodextrin nanoparticles loaded with progesterone. Polym. Sci. Ser. A 46, 1937-1944 (2004).
83. Monza Da Silveira A, Duchene D, Ponchel G. Influence of solubility and partition coefficient on the loading of combined poly(isobutylcyanoacrylate) and hydroxypropyl-α-cyclodextrin nanoparticles by steroids. STP Pharma Sci. 10, 309-314 (2000).
84. Duchene D, Ponchel G. Combined poly(alkyl cyanoacrylate)/cyclodextrin nanoparticles. J. Incl. Phenom. Macrocycl. Chem. 44(1-4), 15-16 (2002).
85. Boudad H, P L, Appel M, Coconnier M-H, Ponchel G. Formulation of combined cyclodextrin poly(alkylcyanoacrylate) nanoparticles on Caco-2 cells monolayers intended for oral administration of saquinavir. STP Pharma Sci. 11, 369-375 (2001).
86. Agueros M, Areses P, Campanero MA, et al. Bioadhesive properties and biodistribution of cyclodextrin-poly(anhydride) nanoparticles. Eur. J. Pharm. Sci. 37(3-4), 231-240 (2009).
87. Maestrelli F, Garcia-Fuentes M, Mura P, Alonso MJ. A new drug nanocarrier consisting of chitosan and hydoxypropylcyclodextrin. Eur. J. Pharm. Biopharm. 63(2), 79-86 (2006).
88. Calvo P, Remuán-Lpez C, Vila-Jato JL, Alonso MJ. Novel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carriers. J. Appl. Polym. Sci. 63(1), 125-132 (1997).
89. Krauland AH, Alonso MJ. Chitosan/cyclodextrin nanoparticles as macromolecular drug delivery system. Int. J. Pharm. 340(1-2), 134-142 (2007).
90. Ieva E, Trapani A, Cioffi N, Ditaranto N, Monopoli A, Sabbatini L. Analytical characterization of chitosan nanoparticles for peptide drug delivery applications. Anal. Bioanal. Chem. 393(1), 207-215 (2009).
91. Chen Y, Mohanraj V, Parkin J. Chitosan-dextran sulfate nanoparticles for delivery of an anti-angiogenesis peptide. Lett. Pept. Sci. 10(5-6), 621-629 (2003).
92. Fernández-Urrusuno R, Romani D, Calvo P, Vila-Jato JL, Alonso MJ. Development of freeze-dried formulation of insulin-loaded chitosan nanoparticles intended for nasal administration. STP Pharma Sci. 9, 429-436 (1999).
93. Li J, Loh XJ. Cyclodextrin-based supramolecular architectures: syntheses, structures, and applications for drug and gene delivery. Adv. Drug Deliv. Rev. 60(9), 1000-1017 (2008).
94. Simoes S, Veiga F, Torres-Labandeira J, Ribeiro A, Concheiro A, Alvarez-Lorenzo C. Syringeable self-assembled cyclodextrin gels for drug delivery. Curr. Top. Med. Chem. 14(4), 494-509 (2014).
95. Messner M, Kurkov SV, Jansook P, Loftsson T. Self-assembled cyclodextrin aggregates and nanoparticles. Int. J. Pharm. 387(1-2), 199-208 (2010).
96. Gref R, Amiel C, Molinard K, et al. New self-assembled nanogels based on host-guest interactions: characterization and drug loading. J. Control. Release 111(3), 316-324 (2006).
97. Renard E, Deratani A, Volet G, Sebille B. Preparation and characterization of water soluble high molecular weight γ-cyclodextrin-epichlorohydrin polymers. Eur. Polym. J. 33(1), 49-57 (1997).
98. Amiel C, Moine L, Sandier A, et al. Macromolecular assemblies generated by inclusion complexes between amphipathic polymers and γ-cyclodextrin polymers in aqueous media. In: Stimuli-Responsive Water Soluble and Amphiphilic Polymers. McCormick CL (Ed.). American Chemical Society, Washington, DC, USA, 58-81 (2000).
99. Daoud-Mahammed S, Couvreur P, Bouchemal K, et al. Cyclodextrin and polysaccharide-based nanogels: entrapment of two hydrophobic molecules, benzophenone and tamoxifen. Biomacromolecules 10(3), 547-554 (2009).
100. Battistini E, Gianolio E, Gref R, et al. High-relaxivity magnetic resonance imaging (MRI) contrast agent based on supramolecular assembly between a gadolinium chelate, a modified dextran, and poly-α-cyclodextrin. Chem. Eur. J. 14(15), 4551-4561 (2008).
101. Deniz E, Kandoth N, Fraix A, et al. Photoinduced fluorescence activation and nitric oxide release with biocompatible polymer nanoparticles. Chem. Eur. J. 18(49), 15782-15787 (2012).
102. Kandoth N, Mosinger J, Gref R, Sortino S. A NO photoreleasing supramolecular hydrogel with bactericidal action. J. Mater. Chem. B 1(28), 3458-3463 (2013).
103. Davis ME. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol. Pharm. 6(3), 659-668 (2009).
104. Burckbuchler V, Wintgens V, Leborgne C, et al. Development and characterization of new cyclodextrin polymer-based DNA delivery systems. Bioconjugate Chem. 19(12), 2311-2320 (2008).
105. Cavalli R, Trotta F, Tumiatti W. Cyclodextrin-based nanosponges for drug delivery. J. Incl. Phenom. Macrocycl. Chem. 56(1-2), 209-213 (2006).
106. Mognetti B, Barberis A, Marino S, et al. In vitro enhancement of anticancer activity of paclitaxel by a Cremophor free cyclodextrin-based nanosponge formulation. J. Incl. Phenom. Macrocycl. Chem. 74(1-4), 201-210 (2012).
107. Roux M, Perly B, Djedaini-Pilard F. Self-assemblies of amphiphilic cyclodextrins. Eur. Biophys. J. 36(8), 861-867 (2007).
108. Ghosh I, Nau WM. The strategic use of supramolecular pKa shifts to enhance the bioavailability of drugs. Adv. Drug Deliv. Rev. 64(9), 764-783 (2012).
109. Walker S, Oun R, Mcinnes FJ, Wheate NJ. The potential of cucurbit[n]urils in drug delivery. Isr. J. Chem. 51(5-6), 616-624 (2011).
110. Isaacs L. Cucurbit[n]urils: from mechanism to structure and function. Chem. Commun. 14(6), 619-629 (2009).
111. Mock WL, Shih NY. Structure and selectivity in host-guest complexes of cucurbituril. J. Org. Chem. 51(23), 4440-4446 (1986).
112. Loh XJ. Supramolecular host-guest polymeric materials for biomedical applications. Mater. Horiz. 2014(1)(2014).
113. Wheate NJ, Buck DP, Day AI, Collins JG. Cucurbit[n]uril binding of platinum anticancer complexes. Dalton Trans. 21(3), 451-458 (2006).
114. Plumb JA, Venugopal B, Oun R, et al. Cucurbit[7]uril encapsulated cisplatin overcomes cisplatin resistance via a pharmacokinetic effect. Metallomics 4(6), 561-567 (2012).
115. Ma W-J, Chen J-M, Jiang L, Yao J, Lu T-B. The delivery of triamterene by cucurbit[7]uril: synthesis, structures and pharmacokinetics study. Mol. Pharm. 10(12), 4698-4705 (2013).
116. Park KM, Suh K, Jung H, et al. Cucurbituril-based nanoparticles: a new efficient vehicle for targeted intracellular delivery of hydrophobic drugs. Chem. Commun. 1, 71-73 (2009).
117. Kim E, Kim D, Jung H, et al. Facile, template-free synthesis of stimuli-responsive polymer nanocapsules for targeted drug delivery. Angew. Chem. Int. Ed. 49(26), 4405-4408 (2010).
118. Loh XJ, Del Barrio J, Toh PPC, et al. Triply triggered doxorubicin release from supramolecular nanocontainers. Biomacromolecules 13(1), 84-91 (2012).
119. Deshayes S, Kasko AM. Polymeric biomaterials with engineered degradation. J. Polym. Sci. Part A. Polym. Chem. 51(17), 3531-3566 (2013).
120. Ludwig R, Dzung N. Calixarene-based molecules for cation recognition. Sensors 2(10), 397-416 (2002).
121. Diamond D, Nolan K. Peer reviewed: calixarenes: Designer ligands for chemical sensors. Anal. Chem. 73(1), 22 A-29 A (2001).
122. Baldini L, Casnati A, Sansone F, Ungaro R. Calixarene-based multivalent ligands. Chem. Soc. Rev. 36(2), 254-266 (2007).
123. Steed JW, Johnson CP, Barnes CL, et al. Supramolecular shemistry of p-sulfonatocalix[5]arene: A water-soluble, bowl-shaped host with a large molecular cavity. J. Am. Chem. Soc. 117(46), 11426-11433 (1995).
124. Tu C, Zhu L, Li P, et al. Supramolecular polymeric micelles by the host-guest interaction of star-like calix[4]arene and chlorin e6 for photodynamic therapy. Chem. Commun. 47(21), 6063-6065 (2011).
125. Lee M, Lee S-J, Jiang L-H. Stimuli-responsive supramolecular nanocapsules from amphiphilic calixarene assembly. J. Am. Chem. Soc. 126(40), 12724-12725 (2004).
126. Sansone F, Dudic M, Donofrio G, et al. DNA condensation and cell transfection properties of guanidinium calixarenes: dependence on macrocycle lipophilicity, size, and conformation. J. Am. Chem. Soc. 128(45), 14528-14536 (2006).
127. Bagnacani V, Sansone F, Donofrio G, Baldini L, Casnati A, Ungaro R. Macrocyclic nonviral vectors: high cell transfection efficiency and low toxicity in a lower rim guanidinium calix[4]arene. Org. Lett. 10(18), 3953-3956 (2008).
128. Rodik RV, Klymchenko AS, Jain N, et al. Virus-sized DNA nanoparticles for gene delivery based on micelles of cationic calixarenes. Chemistry 17(20), 5526-5538 (2011).
129. Wang K, Guo D-S, Wang X, Liu Y. Multistimuli responsive supramolecular vesicles based on the recognition of p-sulfonatocalixarene and its controllable release of doxorubicin. ACS Nano 5(4), 2880-2894 (2011).
130. Yaghi OM, Okeeffe M, Ockwig NW, Chae HK, Eddaoudi M, Kim J. Reticular synthesis and the design of new materials. Nature 423(6941), 705-714 (2003).
131. Eddaoudi M, Moler DB, Li H, et al. Modular chemistry: secondary building units as a basis for the design of highly porous and robust metal-organic carboxylate frameworks. Acc. Chem. Res. 34(4), 319-330 (2001).
132. Kitagawa S, Kitaura R, Noro S-I. Functional porous coordination polymers. Angew. Chem. Int. Ed. 43(18), 2334-2375 (2004).
133. Ferey G, Mellot-Draznieks C, Serre C, Millange F. Crystallized frameworks with giant pores: are there limits to the possible? Acc. Chem. Res. 38(4), 217-225 (2005).
134. Ferey G. Hybrid porous solids: past, present, future. Chem. Soc. Rev. 37(1), 191-214 (2008).
135. Horcajada P, Gref R, Baati T, et al. Metal-organic frameworks in biomedicine. Chem. Rev. 112(2), 1232-1268 (2011).
136. Horcajada P, Chalati T, Serre C, et al. Porous metal-organic-framework nanoscale carriers as a potential platform for drug delivery and imaging. Nat. Mater. 9(2), 172-178 (2010).
137. Huxford RC, Della Rocca J, Lin W. Metal-organic frameworks as potential drug carriers. Curr. Opin. Chem. Biol. 14(2), 262-268 (2010).
138. Seo Y-K, Yoon JW, Lee JS, et al. Large scale fluorine-free synthesis of hierarchically porous iron(III) trimesate MIL-100(Fe) with a zeolite MTN topology. Microporous Mesoporous Mater. 157, 137-145 (2012).
139. Agostoni V, Horcajada P, Rodriguez-Ruiz V, et al. Green fluorine-free mesoporous iron(III) trimesate nanoparticles for drug delivery. Green Materials 1(4), 209-217 (2013).
140. Horcajada P, Surble S, Serre C, et al. Synthesis and catalytic properties of MIL-100(Fe), an iron(iii) carboxylate with large pores. Chem. Commun. (27), 2820-2822 (2007).
141. Ferey G, Mellot-Draznieks C, Serre C, et al. A chromium terephthalate-based solid with unusually large pore volumes and surface area. Science 309(5743), 2040-2042 (2005).
142. Agostoni V, Chalati T, Horcajada P, et al. Towards an improved anti-HIV activity of NRTI via metal-organic frameworks nanoparticles. Adv. Healthc. Mater. 2(12), 1630-1637 (2013).
143. Agostoni V, Anand R, Monti S, et al. Impact of phosphorylation on the encapsulation of nucleoside analogues within porous iron(iii) metal-organic framework MIL-100(Fe) nanoparticles. J. Mater. Chem. B 1(34), 4231-4242 (2013).
144. Di Nunzio MR, Agostoni V, Cohen B, Gref R, Douhal A. A "ship in a bottle" strategy to load a hydrophilic anticancer drug in porous metal organic framework nanoparticles: efficient encapsulation, matrix stabilization, and photodelivery. J. Med. Chem. 57(2), 411-420 (2014).
145. Baati T, Njim L, Neffati F, et al. In depth analysis of the in vivo toxicity of nanoparticles of porous iron(iii) metal-organic frameworks. Chem. Sci. 4(4), 1597-1607 (2013).
146. Serre C, Mellot-Draznieks C, Surble S, Audebrand N, Filinchuk Y, Ferey G. Role of solvent-host interactions that lead to very lage swelling of hybrid frameworks. Science 315(5820), 1828-1831 (2007).
147. Miller SR, Heurtaux D, Baati T, Horcajada P, Greneche J-M, Serre C. Biodegradable therapeutic MOFs for the delivery of bioactive molecules. Chem. Commun. 46(25), 4526-4528 (2010).
148. Rieter WJ, Taylor KML, An H, Lin W, Lin W. Nanoscale metal-organic frameworks as potential multimodal contrast enhancing agents. J. Am. Chem. Soc. 128(28), 9024-9025 (2006).
149. Taylor KML, Kim JS, Rieter WJ, An H, Lin W, Lin W. Mesoporous silica nanospheres as highly efficient MRI contrast agents. J. Am. Chem. Soc. 130(7), 2154-2155 (2008).
150. Salavati-Niasari M, Mohandes F. From zeolite to host-guest nanocomposite materials. In: Advances in Diverse Industrial Applications of Nanocomposites. Reddy B (Ed.). InTech, Rijeka, Croatia (2011).
151. Duan Q, Cao Y, Li Y, et al. pH-responsive supramolecular vesicles based on water-soluble pillar[6]arene and ferrocene derivative for drug delivery. J. Am. Chem. Soc. 135(28), 10542-10549 (2013).
152. Xue M, Yang Y, Chi X, Zhang Z, Huang F. Pillararenes, a new class of macrocycles for supramolecular chemistry. Acc. Chem. Res. 45(8), 1294-1308 (2012).
153. Yu G, Han C, Zhang Z, et al. Pillar[6]arene-based photoresponsive host-guest complexation. J. Am. Chem. Soc. 134(20), 8711-8717 (2012).
154. Yu G, Xue M, Zhang Z, Li J, Han C, Huang F. A water-soluble pillar[6]arene: synthesis, host-guest chemistry, and its application in dispersion of multiwalled carbon nanotubes in water. J. Am. Chem. Soc. 134(32), 13248-13251 (2012).
155. Yu G, Zhou X, Zhang Z, et al. Pillar[6]arene/paraquat molecular recognition in water: high binding strength, pH-responsiveness, and application in controllable self-assembly, controlled release, and treatment of paraquat poisoning. J. Am. Chem. Soc. 134(47), 19489-19497 (2012).